Cogent Biosciences, Inc. Common Stock
$33.01
$0.47 (+1.44%)
$32.94Day Range$33.64
Key Statistics
Market Cap
$5.65B
Shares Outstanding
173.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 29, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$33.07
Day High
$33.64
Day Low
$32.94
Volume
577.5K
VWAP
$33.25
Prev Close
$32.54
Transactions
--
Acc. Volume
--
About Cogent Biosciences, Inc. Common Stock
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
PHARMACEUTICAL PREPARATIONSSIC 2834258 employees180 THIRD AVENUE, WALTHAM, MA617-945-5576IPO Mar 29, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001622229
- Composite FIGI
- BBG007DHZQR7
- Share Class FIGI
- BBG007DHY102
- Ticker Root
- COGT
- SIC Code
- 2834
About Cogent Biosciences, Inc. Common Stock (COGT) Stock
Cogent Biosciences, Inc. Common Stock (COGT) closed the 2026-09-17 session at $33.01, up 1.44% versus the previous close (+0.47). The stock opened at $33.07 and traded between $32.94 and $33.64 during that session. Session trading volume was 578K shares. The volume-weighted average price (VWAP) is $33.25.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Cogent Biosciences, Inc. Common Stock has a market capitalization of $5.65 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. COGT is listed on the XNAS exchange. The company employs approximately 258 people. Cogent Biosciences, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2018-03-29.
On this page you can find market COGT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.